Published 2:01 PM PDT, September 8, 2026
Lakewood-Amedex will highlight its business and clinical development strategy, recent achievements, and upcoming milestones at the H.C. Wainwright Global Investment Conference.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT)
SARASOTA, FL, UNITED STATES, September 8, 2026 / EINPresswire.com / -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT, the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City.
As a new B2i Digital Featured Company, a full company profile is coming soon to https://b2idigital.com/featured-companies
Details of the presentation are as follows:
• Event: H.C. Wainwright 28th Annual Global Investment Conference
• Date: September 14-16, 2026
During the conference, Dr. Cooper will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
SOURCE: Lakewood-Amedex Biotherapeutics Inc.
David Shapiro
B2i Digital, Inc.
+1 212-579-4844
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.